How founders of reagent, kit, assay, instrument, and software tool companies use commercial strategy to raise their next round and reach first revenue faster.

Most biotech tool companies are founded on a genuine technical advance: a more sensitive assay, a cleaner library prep, a faster sample-prep workflow, a novel reagent chemistry, an instrument that removes a real bottleneck. The science is usually the strongest thing in the building. The problem is that the science does not raise the next round, and it does not generate the first purchase order. Investors fund commercial trajectories. Early adopters buy outcomes. A pre-revenue tool company that cannot yet articulate and start to demonstrate a credible path from technology to revenue is leaving both money and time on the table.

QUICK ANSWER Pre-revenue biotech tool companies benefit from a commercialization partner because it delivers two things that capital and technical talent cannot produce on their own: a commercial plan credible enough for investors to underwrite, and a repeatable system for finding, converting, and retaining early adopters that compresses the time to first revenue, all before the company can justify the cost of a full commercial team.

 

This guide answers the questions a pre-revenue tool company founder, CEO, or CSO would ask, or would ask an AI assistant, when deciding whether commercial help is worth it before the product is generating revenue.

Why should a pre-revenue biotech tool company work with a commercialization firm?

DIRECT ANSWER A pre-revenue biotech tool company should work with a commercialization firm because the two things that determine its next 18 months, raising capital and reaching first revenue, both depend on commercial execution the founding team usually has not built before, and a firm can install that capability faster and cheaper than hiring for it.

 

Founders of tool companies are typically scientists or engineers. They are exceptional at the thing the company was built to do. What most have never done is carry a number: define an ideal customer, build a positioning that survives contact with a skeptical PI, run a sample-to-order conversion process, or manage a distributor who is deciding whether your product is worth a slot in the bag.

A commercialization partner closes that gap in two directions at once:

• Upstream, toward investors: it turns “we have great technology” into a defensible, evidence-based commercial plan that a board or a lead investor can underwrite.
• Downstream, toward the market: it builds the actual machinery that turns interest into first revenue: segmentation, messaging, demand generation, a CRM to track it, and a follow-up process that does not depend on the founder remembering to email someone back.

The point of doing this early is not vanity. It is that both fundraising and first revenue take longer than founders expect, and both get materially easier when the commercial story is real rather than aspirational.

What do investors actually want to see in a biotech tool company’s commercial plan?

DIRECT ANSWER Investors want to see that a pre-revenue tool company knows exactly who its first customers are, why those customers will switch, how it will reach them repeatably, and what the early evidence says. They are not looking for a top-down TAM slide, but for a bottom-up, defensible route to the first tranche of revenue.

 

The commercial section of a pitch deck is where most tool-company raises get quietly discounted. Investors have seen hundreds of decks where the technology is impressive and the go-to-market is a bullet list of channels no one has tested. What earns conviction is specificity that only comes from commercial work:

• A named ideal customer profile, not “genomics labs,” but the specific workflow, sample type, incumbent method, and pain point where your product wins.
• A reason to switch that a buyer would actually say out loud, backed by comparison data or early user evidence.
• A repeatable acquisition motion: how the next 20 customers get found, not how the first lucky one did.
• Early signal: sample requests, letters of intent, design partners, a waitlist, pilot conversions, or anything that shows demand is real, not assumed.
• A credible cost-to-acquire and sales-cycle estimate grounded in how life science buyers actually evaluate and validate products.

None of that requires revenue. All of it requires commercial thinking that founders rarely have time to build while also running R&D. A partner produces it as a deliverable, and just as importantly, produces it in a form a sophisticated investor recognizes as real.

Can commercial strategy really help a pre-revenue company raise its next round?

DIRECT ANSWER Yes. Commercial strategy directly de-risks the raise, because at the tool-company stage investors are underwriting the transition from science to a sellable business, and a credible, evidence-backed commercialization plan is often the difference between a technology that is interesting and one that is fundable.

 

Early biotech investing is risk pricing. A pre-revenue tool company carries technical risk, but by the time a company is raising to scale, the technical risk is partly retired and the open question becomes commercial: can this team turn the technology into revenue? That is precisely the risk a commercialization partner is built to reduce.

When the plan shows a specific first market, a tested message, early adopter evidence, and a repeatable motion to get from pilot to purchase order, the founder is no longer asking the investor to take the commercial bet on faith. That shift, from “trust us on go-to-market” to “here is the machine and here is the early data,” changes both the probability of the raise and, frequently, the terms.

Need a commercial plan investors will actually underwrite? PSG Life Sciences works with pre-revenue and early-stage life science tool companies to build the segmentation, positioning, and go-to-market foundation that turns a strong technology into a fundable commercial story. Explore the Start solution  →

Isn’t it too early to invest in commercialization before you have revenue?

DIRECT ANSWER No. The pre-revenue stage is exactly when commercial work has the highest leverage, because positioning, target market, and the acquisition motion are cheapest to get right before they are baked into a website, a sales hire, and a burn rate that assumes they were correct.

 

The instinct to defer commercial work until “we have something to sell” is understandable and usually wrong. By the time a tool company has revenue, it has already chosen a message, a market, and a channel, often by accident based on whichever early customer happened to show up. Unwinding those choices later is expensive.

Doing the work early does not mean building a full sales org before there is anything to sell. It means getting the decisions that compound right while they are still cheap to change: who you are for, why they should switch, and how you will reach them. Those decisions shape the deck, the site, the first hire, and the burn. Getting them right before the money is committed is the highest-return commercial work a pre-revenue company can do.

How does a commercialization partner help a pre-revenue tool company find early adopters?

DIRECT ANSWER A commercialization partner finds early adopters by narrowing the market to the specific labs and workflows where the product’s advantage is undeniable, reaching them with application-specific content and outreach, and running a structured sample-to-order process so the interest a great product generates actually converts instead of leaking away.

 

Early adopters in life science tools are a specific type of buyer: they have an acute problem, they are willing to try something new to solve it, and they are influential enough that their adoption pulls others in. Finding them is not a volume game; it is a precision game. The partner’s job is to:

• Define the beachhead: the narrow application where your product is not just better but obviously better, so the switch is easy to justify.
• Reach the right scientists: use application notes, comparison content, and targeted outreach built around the buyer’s actual search and evaluation behavior, not generic brand messaging.
• Convert interest into evaluation: create a sample-request and pilot process that captures who, what application, what sample type, and what buying potential, with follow-up that actually happens.
• Turn evaluation into revenue and reference: close the first orders and convert early adopters into the case studies and referrals that make the next cohort easier.

This matters because life science buying runs on trust and referral. Scientists move between labs and institutions, and they carry vendor preferences with them. A well-managed early-adopter program is not just first revenue; it is the seed of a referral engine that compounds.

Sitting on a strong product but no repeatable way to generate early customers? PSG Life Sciences helps growth-stage life science tool companies build the demand generation, CRM, and follow-up systems that turn interest into early adopters and early adopters into revenue. See how we help companies Grow  →

How does early commercial work shorten the time to first revenue?

DIRECT ANSWER Early commercial work shortens time to first revenue by removing the trial-and-error most tool companies pay for in wasted months. A focused target market, a tested message, and a working conversion process mean the company spends its runway selling to the right people the right way instead of discovering who and how by accident.

 

Runway is the scarcest resource a pre-revenue company has, and the slowest way to spend it is to learn go-to-market by trial and error while the burn clock runs. The most common pattern is a company that launches broadly, gets scattered interest, chases every lead equally, converts a few by luck, and only months later figures out which segment and message were actually working.

A commercialization partner compresses that cycle by front-loading the decisions that would otherwise be learned the slow way:

• Targeting the beachhead first means every outreach dollar and hour is aimed where the product wins.
• A tested message means fewer conversations die because the buyer never understood the reason to switch.
• A CRM-tracked sample-to-order process means no qualified sample request or quote quietly goes cold, which is the single most common way early revenue is lost.
• Distributor and channel groundwork, where relevant, means the company is not the only one selling.

The result is not magic. It is simply that a company running a real commercial process reaches its first orders in fewer months than one improvising, and every month saved is runway preserved and dilution avoided.

Should a pre-revenue tool company hire a commercial team or use a fractional firm?

DIRECT ANSWER Most pre-revenue tool companies should use fractional commercial leadership before hiring a full-time team, because they need senior strategy and process built before they need day-to-day selling capacity. Hiring a first commercial rep before the playbook exists usually produces frustration and churn, not revenue.

 

The temptation, especially right after a raise, is to hire a VP of Sales or a first commercial rep and hand them the mandate to “go get revenue.” At the pre-revenue stage this often backfires. Without a defined ideal customer, tested positioning, a working CRM, and a qualification process, a new hire spends their first two quarters building all of that themselves, often at significant expense and while questioning whether they made the right career move.

Fractional commercial leadership inverts the sequence. It brings senior sales and marketing experience in to build the playbook, the segmentation, the CRM foundation, and the first repeatable motion, the work that should exist before a full-time hire, not after. Once there is a proven process and enough volume to justify it, the company hires into a system that is ready to receive them, rather than asking a first hire to invent it from scratch.

Deciding between a first commercial hire and getting the strategy right first? PSG Life Sciences provides fractional commercial leadership, providing senior sales and marketing expertise without the cost or risk of a full-time hire, to build the playbook before you build the team. Learn about Fractional Services  →

When should a biotech tool company start commercial work?

DIRECT ANSWER A biotech tool company should start commercial work as soon as it can describe a first credible use case and target user, usually well before product launch, because the questions commercialization answers (who, why, how) inform the raise, the roadmap, and the early-adopter strategy long before the product is finished.

 

There is no single milestone that unlocks commercial readiness, but the useful trigger is earlier than most founders assume. If you can name a first use case and the type of scientist who has that problem, you are ready to begin because the commercial questions are not downstream of the product; they run alongside it. Positioning shapes what you emphasize in development. Ideal-customer work shapes who you recruit as design partners. Early-adopter strategy shapes the fundraising narrative.

Practically, the highest-leverage moments to bring in a commercial partner are: while preparing to raise (to make the plan fundable), immediately after a raise (to deploy the capital into a real motion rather than guesswork), and in the run-up to a product launch (so launch generates pipeline, not just press).

What is the biggest commercial mistake pre-revenue biotech tool founders make?

DIRECT ANSWER The biggest mistake is treating commercialization as a phase that starts after the product is done and the money is raised. In reality, the commercial plan is what makes the raise credible and the early-adopter engine is what turns the product into a business, so deferring both is how pre-revenue tool companies waste runway and under-raise.

 

The failure mode is consistent and expensive. A founding team pours everything into the technology, assumes a great product will find its market, raises on the strength of the science, and only turns to commercialization once the money is in the bank and the pressure to show revenue is on. By then the easy, high-leverage commercial decisions have been made by default, the raise may have come in lower than it should have, and the runway available to learn go-to-market is shorter than it needed to be.

The companies that avoid this do not necessarily have better science. They treat commercial strategy as a parallel workstream to R&D, one that makes the raise stronger, sharpens the product roadmap, and has the early-adopter engine running the day there is something to sell. That is the difference between a strong technology and a growing company.

Bottom Line: How Should a Pre-Revenue Tool Company Approach Commercialization?

DIRECT ANSWER A pre-revenue biotech tool company should treat commercialization as a lever it pulls before revenue, not after. It should use a commercial partner to build a fundable go-to-market plan and a repeatable early-adopter engine, so it raises on stronger footing and reaches first revenue faster than it could by improvising.

 

For a pre-revenue tool company, commercial work is not a cost to be deferred until there is revenue to justify it. It is the work that makes the revenue arrive sooner and the raise land higher. The priorities are straightforward:

• Define the beachhead market and ideal customer before you scale spend against them.
• Build positioning around workflow value and a real reason to switch, not specifications alone.
• Turn that into a commercial plan an investor can underwrite.
• Stand up a CRM and a sample-to-order process so early interest converts instead of leaking.
• Run a focused early-adopter program that produces first revenue and the references that compound it.
• Use fractional commercial leadership to build the playbook before hiring a full-time team.

The tool companies that grow are rarely the ones with the best technology alone. They are the ones that pair strong science with a commercial system built early enough to matter for the raise, the runway, and the first customers who make everything after them easier.

About This Guide

This guide is written by Stephen Manobianco and published by PSG Life Sciences, a HubSpot Gold partner and fractional commercialization firm that works exclusively with biotech, life science, and diagnostic product and service companies. Before PSG, Stephen carried a quota at GENEWIZ, a global genomics services company, where he managed both direct and distributor sales, selling technical products to scientific and procurement buyers, and watching firsthand how labs evaluate, adopt, and switch tools. PSG is built on that commercial-operator perspective: the sales, marketing, CRM, and go-to-market systems described here are implemented client work, not theory from people who have been buyers but never carried a number.

Ready to make your commercial plan fundable and your path to first revenue faster? Talk to PSG Life Sciences about a commercialization assessment for your pre-revenue or early-stage life science tool company, covering positioning, ideal customer, CRM, and early-adopter strategy. Contact PSG Life Sciences  →